anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Risk Summary

There is no information on the presence of solifenacin in human milk, the effects on the breastfed child, or the effects on milk production. Solifenacin is present in mouse milk [see Data].  When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for solifenacin succinate and any potential adverse effects on the breastfed child from solifenacin succinate or from the underlying maternal condition. 

Data

Animal Data

Oral administration of 14C-solifenacin succinate to lactating mice resulted in the recovery of radioactivity in maternal milk. Lactating female mice orally administered solifenacin succinate at a maternally toxic dose of 100 mg/kg/day (3.6 times the systemic exposure at the MRHD) had increased postpartum pup mortality, pups with reduced body weights, or delays in the onset of reflex and physical development. Pups from lactating dams orally administered solifenacin succinate at a dose of 30 mg/kg/day (1.2 times the systemic exposure at the MRHD) had no discernible adverse findings. The concentrations of solifenacin in animal milk does not necessarily predict the concentration of drug in human milk.
The present invention relates to chemically known compounds used and authorized by the FDA with a novel dosage form and application. The micro-dosed interferon clathrate mixture reduces side effects and the response of interferon neutralizing antibodies, or hypersensitivity reactions, allowing preventive utility as a therapeutic aid, its availability, and ease of administration. Also, it decreases the stages that require critical medical care within a synergism in three formulations to protect emerging health personnel in the first line of care for patients with respiratory diseases and COVID 19. Said compositions work as stimulants of innate immunity based on colostrum as an associated immunomodulatory with lysozyme, which is part of the immunity of mucous membranes and tissues, and interferon-alpha 2 beta, signaler and initiator of the immune response to bacterial and viral infections. Said formulation has a double mechanism of action for a) increasing innate immunity and the streng thening of immunological defense mechanisms, b) destructing external pathogenic agents, such as viruses, bacteria, and fungi, including influenza virus and coronavirus. Said elements trigger metabolic and enzymatic defense mechanisms and the blocking of the CD147 cell receptor cell entry gate to SARS-type viruses, and especially SARS- CoV, and SARS-CoV2, allowing an antiviral synergism shared with malaria that explains why hydroxychloroquine can stop its contagiousness and pathogenicity.
The utility model relates to a slow-released medicinal capsule. One end surface of a capsule bag is a plane surface 2, and the other end surface is a bulging surface 3 on which capillary holes 5 are overspread. Medicine 4 in the capsule bag 1 can be released through the capillary holes 5. The utility model has the advantage of novel structural design, and the bulging surface of the capsule bag is applied to an affected part, which can achieve successive medication through the slow release of the capillary holes. Such systemic diseases or local diseases as skin diseases, surgery diseases, gynecopathies, etc., can be treated through transdermal absorption. Additionally, the utility model does not pollute clothes, which brings convenience to patients.
Compositions containing ascorbic acid stabilized by the presence of a phosphonic acid derivative and a metabisulfite. Compositions containing ascorbic acid stabilized by the presence of at least one phosphonic acid derivative and at least one metabisulfite, these being present in sufficient quantity to have a synergistic effect. The weight ratio of metabisulfite/phosphonic acid derivative is 1 - 1000. The preferred metabisulfites are those of alkali(ne earth) metals, ammonium, and their mixtures. The preferred phosphonic acid derivatives are ethylene diamine tetra(methylene phosphonic) acid, hexamethylene diamine tetra(methylene phosphonic) acid, and diethylene triamine penta(methylene phosphonic) acid, their salts and mixtures. The compositions preferably contain 0.005 - 5% of each of the stabilizers, the ascorbic acid content being 0.01 - 20%. They preferably are of pH 5.5 - 7.5 and are formulated for topical application to the skin, mucous membranes, and keratinic fibers. They may also contain water, fatty materials, preservatives, gelling agents, surfactants and emulsifiers, antioxidants, fillers, solvents, perfumes, colors, filters, and active ingredients. Independent claims cover the system for stabilizing ascorbic acid containing a phosphonic acid derivative and a metabisulfite.
The invention discloses insoluble dietary fiber of raisin tree and a preparing method thereof. The raw material is raisin tree fruit or fruit residue thereof after brewing, vinegar production, sugar production, beverage production or active pharmaceutical ingredient extraction. According to the impurity in the raw material and the content, one or a plurality of methods of washing, acid treatment,alkali treatment and decoloring and the like are adopted to remove the impurity, and then dehydrating, drying and superfine grinding are executed. The prepared insoluble dietary fiber of raisin tree is light yellow or ivory powder with the average grain size of 10 to 90 Mum, the content of the insoluble dietary fiber is 50 percent to 100 percent, the retention ability is 1 to 10g/g, the liposuction ability is 1 to 10g/g, the swelling capacity is 1 to 10 mL/g, and the cation exchange resin capacity is 1 to 7 mmoI/g. The insoluble dietary fiber of raisin tree can be used for preparing food, functional food or medicines, or be taken as raw material or auxiliary material of food, functional food or medicines. The method for preparing the insoluble dietary fiber of raisin tree is simple, the production equipment is easily-obtained and has low cost, and the method is suitable for industrialized production.
A system for informing food element decisions in the acquisition of edible materials from any source. The system includes a processor coupled to a memory configured to receive from a user client device a food element descriptor uniquely identifying a particular food element. The system retrieves from a physiological database at least an element of physiological data. The system identifies using at least an element of physiological data and a machine-learning algorithm user constitutional enhancing food elements and user constitutional advancing food elements. The system classifies using a food element classifier a food element descriptor. The system displays on a graphical user interface a constitutional enhancing food element or a constitutional advancing food element.
BACKGROUND AND PURPOSE: Despite being associated with serious adverse outcomes, such as mortality, sarcopenia remains largely undiagnosed in older individuals. This study aimed to assess the awareness, practices, and barriers and enablers to clinical implementation of sarcopenia diagnosis and treatment among geriatric rehabilitation health care professionals in the Netherlands.
METHODS: As part of EMPOWER-GR, a cross-sectional survey among geriatric rehabilitation health care professionals working in the Netherlands was undertaken between September 23, 2020, and January 28, 2021. Professionals were recruited via a geriatric rehabilitation care provider, health care professional associations, professional networks of the research team, and social media. Descriptive statistics were used to assess the study outcomes.
RESULTS AND DISCUSSION: Of the 501 geriatric rehabilitation health care professionals, 12.2% were physicians, 23.0% physical therapist/occupational therapists, 30.3% dietitians, 19.6% nurses, and 11.0% health care assistants. The concept of sarcopenia was known by 83.8% of the participants, 92.5% correctly identified sarcopenia as low muscle mass and strength (and low physical performance), and 73.8% identified sarcopenia as very important in the management of older adults admitted for rehabilitation. Although 26.2% and 18.9% of the participants reported screening and diagnosing sarcopenia, respectively, in their current practice, only 3.0% adequately used the (revised) definition of the European Working Group on Sarcopenia in Older People. When sarcopenia has been diagnosed, 65.0% reported initiating treatment consisting of resistance exercise training (78.7%), food fortification/high-energy or protein diet (85.4%), and oral nutritional supplements (70.4%). Most important barriers to screening and diagnosis were lack of knowledge, access to tools, and equipment and time, while enablers were protocol implementation, access to training, and clear responsibilities.
CONCLUSIONS: Sarcopenia awareness is high among geriatric rehabilitation health care professionals in the Netherlands, but adequate screening and diagnosis is almost nonexistent in current clinical practice, which hampers interventions. Better knowledge, clear responsibilities, and access to tools and protocols, as well as prioritization, are needed for sarcopenia to be diagnosed and treated in geriatric rehabilitation in the Netherlands.
People with gambling concerns will be recruited using targeted advertisements. Potential participants will be screened using an online survey to identify participants meeting criteria for problem gambling. As part of the baseline screening process, measures of current depression and anxiety will be assessed. Eligible participants agreeing to take part in the study will be randomized to one of two versions of an online intervention for gamblers - an intervention that just targets gambling issues (G-only) versus one that contains interventions for anxiety and depression in addition to an intervention for gamblers (G+MH). It is predicted that problem gamblers who do not have co-occurring mental health concerns will display no significant difference between intervention conditions at a six-month follow-up. However, for those with co-occurring mental health concerns, it is predicted that participants receiving access to G+MH website will display significantly reduced gambling outcomes at six-month follow-up as compared to those provided with G-only website.
In addition to the exercise training (stretching and relaxation exercises), which includes stretching and relaxation exercises routinely used in the field of physiotherapy and rehabilitation in primary dysmenorrhea, the patients in the pain neuroscience education arm will be given pain neuroscience education once a week for 2 weeks. Participants in the pain neuroscience education arm will be given pain neuroscience education once a week for 2 weeks after their first menstruation. The training will be repeated with a reminder session at the end of the 2nd menstruation.
Elevated infant fecal concentrations of the bacterial-derived lipid 12,13-dihydroxy-9Z-octadecenoic acid (12,13-diHOME) increase the risk for childhood atopy and asthma. However, the mechanisms by which this lipid contributes to disease development are largely unknown. We hypothesized that macrophages, which are key to both antimicrobial and antigen responses, are functionally and epigenetically modified by 12,13-diHOME leading to short- and long-term dysfunction with consequences for both antimicrobial and antigenic responses. Macrophages exposed to 12,13-diHOME are skewed toward inflammatory IL-1β highCD206low cells, a phenomenon that is further amplified in the presence of common microbial-, aero-, and food-allergens. These IL-1β highCD206low macrophages also exhibit reduced bacterial phagocytic capacity. In primary immune cell coculture assays involving peanut allergen stimulation, 12,13-diHOME promotes both IL-1β and IL-6 production, memory B cell expansion, and increased IgE production. Exposure to 12,13-diHOME also induces macrophage chromatin remodeling, specifically diminishing access to interferon-stimulated response elements resulting in reduced interferon-regulated gene expression upon bacterial lipopolysaccharide stimulation. Thus 12,13-diHOME reprograms macrophage effector function, B-cell interactions and promotes epigenetic modifications that exacerbate inflammatory response to allergens and mutes antimicrobial response along the interferon axis. These observations offer plausible mechanisms by which this lipid promotes early-life pathogenic microbiome development and innate immune dysfunction associated with childhood allergic sensitization.
This is a prospective, randomized, double-blind study of different stimulation patterns in patients undergoing implantation of neurostimulator systems for chronic medically intractable neuropathic pain. Research participants will be individuals who have undergone implantation of neurostimulator electrodes into the spinal column or peripheral nervous system for clinical treatment of neuropathic pain. All patients will already have undergone empiric programming of the stimulator using conventional settings (typically 40-60 Hz, 350-450 usec pulse width). However, other stimulation parameters, including high-frequency stimulation, are also feasible and FDA-approved using the implanted device, and it is possible to do this without producing a sensory percept, which makes it possible to test efficacy in a double blind manner. For this study, two different stimulation parameters will be tested during four two-week periods: 1000 Hz and placebo. Clinical response and side effect profile for each setting will be measured.
Participants received erenumab 70 mg on day 1 and at weeks 4 and 8 by subcutaneous injection in the double-blind treatment phase. Participants continued to receive erenumab 70 mg administered by subcutaneous injection at weeks 12, 16, 20, 24, 28, 32, and 36 in the open-label treatment phase.
Intravenous Ascorbic Acid (Vitamin C) is a widely used alternative cancer treatment. This trial will study an intravenous Vitamin C treatment for persons with liver cancer that has spread, who are also receiving Sorafenib (a standard cancer drug), to see whether the combination of Vitamin C and Sorafenib is safe and well tolerated. Phase I will involve 6 persons who will receive the Vitamin C for 8 weeks to more specifically assess the safety of getting Vitamin C in combination with Sorafenib. Phase II will be randomized to receive either Vitamin C plus Sorafenib or Sorafenib alone for 16 weeks. If Vitamin C has a beneficial effect on tumour cells, patients may experience a regression of tumor or tumor markers. Additional benefits include scans at no charge to the patient.
INTRODUCTION: Rehabilitation medicine in a tertiary care hospital involves attending to many patients affected by intensive care unit (ICU)-associated weakness (ICU-AW) and hospital-associated deconditioning (HAD). These conditions contribute to poor long-term functional outcomes and increased mortality. We explored the role of short-term adjunctive androgen therapy in this group of patients in improving the rehabilitative outcomes.
METHODS: This was a retrospective analysis of five patients with either ICU-AW or HAD who were given testosterone replacement therapy (TRT) or oxandrolone for a total of 2 weeks during the period from April to November 2020 was undertaken. During the 2-week trial period, the subjects underwent standard rehabilitation therapy.
RESULTS: Grip strength was used as the primary outcome measure, and the mean improvement was 4.2 kg (+24.9%), which is encouraging in a 2-week timeframe. This was matched with good functional recovery in terms of distance ambulated and less assistance needed for ambulation. Sex hormone analysis was also done before initiation of TRT, and it showed that four out of five of the subjects were biochemically hypogonadal. None of the subjects dropped out or experienced any significant adverse events over the 2-week trial period. All the subjects except one improved to full independence at 3 months post-discharge.
CONCLUSION: TRT has the potential to be used as a useful adjunct to standard rehabilitation in enhancing functional recovery in critically ill patients. A multidisciplinary approach would ensure that suitable patients benefit from optimal nutrition, optimal rehabilitation and synergistic testosterone therapy in a clinically sound and resource-efficient fashion.
Unimaginable are the difficulties faced by patients affected by sensory-motor disabilities while executing day to day activities. The flamboyant progress that has made in other areas of medical science does not translate itself in diagnosing them. Early detection and personalized therapy of these disorders is still out of reach. Present disclosure provides systems and methods for optimizing a joint cost function and detecting neuro muscular profiles (e.g., state of user under observation) thereof by implementing a model that quantifies these disorders in terms of a cost functional, which captures the trade-off between the torques applied and the velocities experienced at the joints. Estimation of this cost functional, otherwise known as Inverse optimal control was then carried out using an optimization procedure. To validate ability of estimated cost functional to distinguish weakly distinct neuro-motor conditions, Microsoft Kinect® motion capture data from normal subjects and a patient population with mild sensory-motor disabilities.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic excellent in removing old keratinous layer or keratinous plugs and also without inducing irritation.  <P>SOLUTION: This cosmetic is provided by incorporating (1) 70-90 wt. % polyhydric alcohol, (2) granules and (3) an anionic surfactant in a cosmetic material. Substantially no water content is contained. As the polyhydric alcohol, an antibacterial polyhydric alcohol is preferably incorporated. As the granules, those having fine particle diameter such as passing 200 mesh are used and granulated crystalline cellulose is preferably used. As the anionic surfactant, a sulfosuccinic acid ester is preferable. The cosmetic is excellent in activity of removing the old keratinous layer or keratinous plugs and does almost not induce irritation on its use and suitable as a "cosmetic for repairing roughness".  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Eating behavior is controlled by many factors, including appetite; food availability; family, peer, and cultural practices; and attempts at voluntary control. Eating disorders are characterized by a voluntary control of eating behavior, causing serious disturbances in normal eating habits. People with eating disorders demonstrate an extreme and unhealthy reduction or increase in food intake, as well as feelings of distress or extreme concern about body shape or weight. The three most common types of eating disorders are anorexia nervosa, bulimia nervosa, and binge eating disorder. People with anorexia nervosa have an intense fear of gaining weight or becoming fat. They are usually underweight, and resist maintaining a body weight at or above the minimum normal weight for their age and height. People with bulimia nervosa are less frequently underweight. Their eating habits are characterized by episodes of bingeing, followed by episodes of purging. Similarly, people with binge eating disorder have eating habits characterized by episodes of binge eating, but no purging. Studies on the basic biology of appetite control and the effects of overeating and starvation have revealed extensive information about eating disorders, but there are still questions to be answered. This study will use a sipping and spitting exercise to better understand the brain's response to food intake in people with eating disorders.

Participants in this observational study will first report to the Biological Studies Unit (BSU) for a screening visit. Participants will be provided with a series of sweetened beverages to taste and spit out. The beverages will be made with water, Kool-Aid mix, and sugar or artificial sweetener. Participants will rate the sweetness of each beverage and how much they like it. They will then practice sipping the beverage through a straw and spitting it out without swallowing. Those participants who feel comfortable with the sipping and spitting exercise will report to the BSU for 10 sipping and spitting exercises. The exercises may be scheduled on up to 4 separate days, and may last up to 2 hours per day. Participants will eat a standardized breakfast on the morning of the study, and then will not eat again until they report to the BSU 4 hours later. Participants will sit alone in a room alone, and sip and spit beverages for up to 5 minutes at a time. Between sipping and spitting sessions, participants will complete surveys about hunger and other sensations. They will also rinse their mouths out with baking soda and water to clear the taste of the previous beverage and to prevent discoloration of the mouth from the Kool-Aid. Measurements will include the amount of beverage sipped at a time, and how quickly each was sipped.
Acupuncture will be performed 3 times per week, total 9 sessions, during 3 weeks. Epidural nerve block and medial branch block will be performed once per week, total 3 sessions, during 3 weeks.
A composite magnetic nanoparticle drug delivery system provides targeted controlled release chemotherapies for cancerous tumors and inflammatory diseases. The magnetic nanoparticle includes a biocompatible and biodegradable polymer, a magnetic nanoparticle, the biological targeting agent human serum albumin, and a therapeutic pharmaceutical composition. The composite nanoparticles are prepared by oil-in-oil emulsion/solvent evaporation and high shear mixing. An externally applied magnetic field draws the magnetic nanoparticles to affected areas. The biological targeting agent draws the nanoparticles into the affected tissues. Polymer degradation provides controlled time release delivery of the pharmaceutical agent.
The invention relates to an application of sulforaphane in improving the reproductive performance of mammals, which can promote the proliferation and the activity of in vitro granular cells and inhibit the apoptosis of the granular cells by utilizing the sulforaphane. Sulforaphane promotes the production of estradiol and the expression of steroid synthase genes such as granulosa cells StAR and CYP19A1 in vitro. Sulforaphane promotes the expression of the FSH receptor of granulosa cells in vitro. Sulforaphane promotes development of mouse ovary and increases weight of ovary. Sulforaphane promotes the proliferation of granulosa cells in vivo. The sulforaphane promotes the development of ovarian follicles of mice, increases the number of the follicles and increases the number of ovulations. The daily ration of the weaned sow added with the sulforaphen obviously improves the litter size of the sow. The invention provides a new application of the sulforaphane, greatly improves the application value of the sulforaphane, enlarges the application range of the sulforaphane, expands the new field of the sulforaphane, and has wide application prospect and commercial value.